{"filing":{"accession_number":"0001437749-26-028628","cik":"0001016504","ticker":"INBP","company_name":"INTEGRATED BIOPHARMA INC","form":"8-K","filing_date":"2026-08-20","report_date":"2026-08-20","primary_document":"inbp20260820_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1016504/000143774926028628/inbp20260820_8k.htm"},"events":[{"id":28823,"run_id":26379,"accession_number":"0001437749-26-028628","anchor_item_number":"8.01","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"summary":"The filing discloses the appointment of Michael Richtmyer as Head of Operations for Manhattan Drug Company, Inc., a wholly owned subsidiary of Integrated BioPharma. The press release emphasizes his 35+ years of senior operations experience and his role leading \"operational strategies and execution across MDC\" with responsibility for manufacturing, supply chain, quality, and growth. This is a material executive appointment to a senior leadership position at a key operating subsidiary.","company_name":"INTEGRATED BIOPHARMA INC","ticker":"INBP","filing_date":"2026-08-20","form":"8-K","submitted_at":null,"items":[{"id":30881,"accession_number":"0001437749-26-028628","item_number":"8.01","item_title":"OTHER EVENTS.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The filing discloses the appointment of Michael Richtmyer as Head of Operations for Manhattan Drug Company, Inc., a wholly owned subsidiary of Integrated BioPharma. The press release emphasizes his 35+ years of senior operations experience and his role leading \"operational strategies and execution across MDC\" with responsibility for manufacturing, supply chain, quality, and growth. This is a material executive appointment to a senior leadership position at a key operating subsidiary.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-20T19:27:37.283101+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":30881,"accession_number":"0001437749-26-028628","item_number":"8.01","item_title":"OTHER EVENTS.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The filing discloses the appointment of Michael Richtmyer as Head of Operations for Manhattan Drug Company, Inc., a wholly owned subsidiary of Integrated BioPharma. The press release emphasizes his 35+ years of senior operations experience and his role leading \"operational strategies and execution across MDC\" with responsibility for manufacturing, supply chain, quality, and growth. This is a material executive appointment to a senior leadership position at a key operating subsidiary.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-20T19:27:37.283101+00:00","company_name":"INTEGRATED BIOPHARMA INC","ticker":"INBP","filing_date":"2026-08-20"}]}